Claims for Patent: 7,179,483

Summary for Patent: 7,179,483

Title:	Compositions and methods for transdermal oxybutynin therapy
Abstract:	The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Inventor(s):	Ebert; Charles D. (Salt Lake City, UT), Sanders; Steven W. (Salt Lake City, UT)
Assignee:	Watson Pharmaceuticals, Inc. (Corona, CA)
Application Number:	10/913,019
Patent Claims:	1. A method of treating with oxybutynin a subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of: administering a transdermal formulation comprising oxybutynin to a subject to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1, wherein the transdermal formulation optionally includes a permeation enhancer, and wherein the transdermal formulation is in the form of: (a) topical formulation selected from the group consisting of ointments, lotions, gels, pastes, mousses, aerosols and skin creams, or (b) transdermal patches selected from the group consisting of adhesive matrix patches and liquid reservoir systems. 2. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1. 3. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1. 4. The method of claim 1, wherein the oxybutynin in the plasma is (R)-oxybutynin, (S)-oxybutynin, or a combination thereof. 5. The method of claim 1, wherein the metabolite of oxybutynin is N-desethyloxybutynin. 6. The method of claim 5, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof. 7. The method of claim 4, wherein the AUC ratio of (R)-oxybutynin to (S)-oxybutynin is about 0.7:1. 8. The method of claim 5, wherein the AUC ratio of(R)-N-desethyloxybutynin to (R)-oxybutynin is from about 0.4:1 to about 1.6:1. 9. The method of claim 8, wherein the AUC ratio of (R)-N-desethyloxybutynin (R)-oxybutynin is about 1:1. 10. The method of claim 6, wherein the AUC ratio of (R)-N-desethyloxybutynin to (S)-N-desethyloxybutynin is from about 0.5:1 to about 1.3:1. 11. The method of claim 10, wherein the AUC ratio of (R)-N-desethyloxybutynin to (S)-N-desethyloxybutynin is about 0.9:1. 12. The method of claim 1, wherein the oxybutynin metabolite plasma concentration reaches a peak plasma value of less than about 8 ng/ml. 13. The method of claim 1, wherein the oxybutynin metabolite plasma concentration reaches a peak value of less than about 5 ng/ml. 14. The method of claim 1, wherein the adverse drug experience is an experience selected from the group consisting of: gastrointestinal/genitourinary, nervous system, cardiovascular, dermatological, and opthalmic experiences, or a combination thereof. 15. The method of claim 1, where the permeation enhancer is a member selected from the group consisting essentially of: fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol triesters, glycerol diesters, glycerol monoesters, triacetin, short chain alcohols, urea, and mixtures thereof. 16. The method of claim 15, wherein the permeation enhancer is triacetin. 17. The method of claim 1, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin. 18. The method of claim 1, wherein the oxybutynin is R-oxybutynin. 19. The method of claim 1, wherein the oxybutynin is S-oxybutynin. 20. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and reaches a peak plasma concentration of N-desethyloxybutynin from about 0.5 ng/ml to about 8 ng/ml. 21. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and reaches a peak plasma concentration of N-desethyloxybutynin less than about 5 ng/ml. 22. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and reaches a peak plasma concentration of N-desethyloxybutynin from about 1.0 ng/ml to about 3 ng/ml. 23. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and the N-desethyloxybutynin AUC does not exceed the oxybutynin AUC by more than a ratio of about 2:1. 24. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and reaches a peak plasma concentration of N-desethyloxybutynin about 3 ng/ml. 25. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.5:1 to about 4:1. 26. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 1:1 to 5:1. 27. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.8:1 to about 2.5:1. 28. The method of claim 3, wherein the oxybutynin metabolite is N-desethyloxybutynin. 29. The method of claim 1, wherein oxybutynin has plasma concentrations below about 2.0 ng/ml at about 6 hours after administration. 30. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and the N-desethyloxybutynin has plasma concentrations below about 2.0 ng/ml at about 6 hours after administration. 31. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and oxybutynin and N-desethyloxybutynin have plasma concentrations below about 8 ng/ml at about 24 hours after initial administration. 32. The method of claim 1, wherein the oxybutynin metabolite is N-desethyloxybutynin and at steady state, the oxybutynin and N-desethyloxybutynin have plasma concentrations below about 8 ng/ml for the duration of administration. 33. The method of claim 32, wherein the duration of administration is from about 24 to about 96 hours. 34. The method of claim 9, wherein the transdermal composition is administered for a duration of from about 24 to about 96 hours. 35. The method of claim 10, wherein a peak plasma concentration and AUC for (R)-N-desethyloxybutynin are about equal to or less than a peak plasma concentration and AUC for (S)-N-desethyloxybutynin. 36. The method of claim 8, wherein a peak plasma concentration and AUC for (R)-oxybutynin are approximately equal to a peak plasma concentration and AUC for (R)-N-desethyloxybutynin. 37. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration of less than about 4 ng/mL. 38. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration between about 0.25 ng/ml to about 4 ng/ml. 39. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration of about 1.5 ng/ml. 40. The method of claim 6, wherein (R)-N-desethyloxybutynin has an AUC of about 100 ng.times.hr/ml. 41. The method of claim 6, wherein (R)-N-desethyloxybutynin has an AUC of from about 30 ng.times.hr/ml to about 170 ng.times.hr/ml. 42. The method of claim 6, wherein (R)-N-desethyloxybutynin has plasma concentration below about 1 ng/ml at about 6 hours after initiation of administration. 43. The method of claim 6, wherein (R)-N-desethyloxybutynin has plasma concentration below about 2 ng/ml at about 24 hours after initiation of administration. 44. The method of claim 15, wherein the permeation enhancer is urea.